Abivax SA (GB:0RA9)
LSE:0RA9
Holding GB:0RA9?
Track your performance easily

Abivax SA (0RA9) Income Statement

0 Followers

Abivax SA Income Statement

Last quarter (Q2 2024), Abivax SA's total revenue was €―, a decrease of ― from the same quarter last year. In Q2, Abivax SA's net income was €―. See Abivax SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
€ 688.00M€ 489.00M-€ 4.58M€ 37.00K€ 63.00K
Cost of Revenue
----€ 0.00€ 1.00K
Gross Profit
€ 688.00M€ 489.00M-€ 4.58M€ 37.00K€ 62.00K
Operating Expense
€ 543.00M€ 150.00M€ 132.00M€ 55.79M€ 42.60M€ 38.07M
Operating Income
€ 145.00M€ 27.00M€ -132.00M€ -51.20M€ -42.56M€ -38.01M
Net Non Operating Interest Income Expense
€ -68.00M€ -62.00M€ -15.99M€ 4.10M€ -3.13M€ -2.32M
Other Income Expense
€ 167.00M€ -17.00M€ -5.82M---
Pretax Income
€ -92.00M€ 570.00M€ -147.74M€ -60.74M€ -45.56M€ -40.13M
Tax Provision
€ -16.00M€ 112.00M--€ -4.20M€ -2.58M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ -77.00M€ 454.00M€ -147.74M€ -60.74M€ -41.36M€ -37.55M
Basic EPS
--€ -3.43---
Diluted EPS
--€ -3.43---
Basic Average Shares
--€ 43.07M---
Diluted Average Shares
--€ 43.07M---
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
----€ 548.00K€ 504.00K
Total Expenses
€ 543.00M€ 150.00M€ 132.00M€ 55.79M€ 42.60M€ 38.07M
Net Income From Continuing And Discontinued Operation
€ -77.00M€ 454.00M€ -147.74M€ -60.74M€ -41.36M€ -37.55M
Normalized Income
-€ 373.50M--€ -41.47M€ -37.74M
Interest Expense
----€ 3.15M€ 2.06M
EBIT
-€ 294.00M--€ -42.41M€ -38.06M
EBITDA
-€ 294.00M--€ -42.25M€ -38.00M
Currency in EUR

Abivax SA Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis